Oncolys BioPharma Inc. (4588.T)
JPY 568.0
(-1.9%)
JPY 568.0
(-1.9%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -972.59 Million JPY | 26.19% |
| 2022 | -1.31 Billion JPY | 55.35% |
| 2021 | -2.95 Billion JPY | -91.28% |
| 2020 | -1.54 Billion JPY | 45.18% |
| 2019 | -2.81 Billion JPY | -36.52% |
| 2018 | -2.06 Billion JPY | 14.56% |
| 2017 | -2.41 Billion JPY | -10.9% |
| 2016 | -2.17 Billion JPY | 31.51% |
| 2015 | -3.17 Billion JPY | 23.98% |
| 2014 | -4.17 Billion JPY | 17.44% |
| 2013 | -5.06 Billion JPY | -1149.42% |
| 2012 | -405.09 Million JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -506.65 Million JPY | 57.42% |
| 2024 Q1 | -1.18 Billion JPY | -22.33% |
| 2023 Q2 | -896.31 Million JPY | 14.58% |
| 2023 Q1 | -1.04 Billion JPY | 20.36% |
| 2023 Q4 | -972.59 Million JPY | -9.7% |
| 2023 Q3 | -886.61 Million JPY | 1.08% |
| 2023 FY | -972.59 Million JPY | 26.19% |
| 2022 Q4 | -1.31 Billion JPY | 34.29% |
| 2022 FY | -1.31 Billion JPY | 55.35% |
| 2022 Q1 | -2.76 Billion JPY | 6.36% |
| 2022 Q2 | -2.32 Billion JPY | 15.99% |
| 2022 Q3 | -2 Billion JPY | 13.63% |
| 2021 Q2 | -4.08 Billion JPY | 6.87% |
| 2021 Q3 | -3.41 Billion JPY | 16.47% |
| 2021 Q4 | -2.95 Billion JPY | 13.54% |
| 2021 FY | -2.95 Billion JPY | -91.28% |
| 2021 Q1 | -4.38 Billion JPY | -184.42% |
| 2020 Q1 | -2.38 Billion JPY | 15.43% |
| 2020 FY | -1.54 Billion JPY | 45.18% |
| 2020 Q2 | -2.03 Billion JPY | 14.33% |
| 2020 Q3 | -1.55 Billion JPY | 23.83% |
| 2020 Q4 | -1.54 Billion JPY | 0.66% |
| 2019 Q1 | -1.74 Billion JPY | 15.57% |
| 2019 Q4 | -2.81 Billion JPY | -13.19% |
| 2019 Q3 | -2.48 Billion JPY | 11.21% |
| 2019 FY | -2.81 Billion JPY | -36.52% |
| 2019 Q2 | -2.8 Billion JPY | -60.89% |
| 2018 Q3 | -1.97 Billion JPY | -38.33% |
| 2018 Q4 | -2.06 Billion JPY | -4.25% |
| 2018 FY | -2.06 Billion JPY | 14.56% |
| 2018 Q2 | -1.42 Billion JPY | 20.79% |
| 2018 Q1 | -1.8 Billion JPY | 25.2% |
| 2017 Q2 | -2.54 Billion JPY | -12.12% |
| 2017 FY | -2.41 Billion JPY | -10.9% |
| 2017 Q4 | -2.41 Billion JPY | 11.01% |
| 2017 Q3 | -2.71 Billion JPY | -6.39% |
| 2017 Q1 | -2.27 Billion JPY | -4.48% |
| 2016 Q4 | -2.17 Billion JPY | -8.65% |
| 2016 Q3 | -2 Billion JPY | 12.36% |
| 2016 Q2 | -2.28 Billion JPY | 23.15% |
| 2016 Q1 | -2.97 Billion JPY | 6.41% |
| 2016 FY | -2.17 Billion JPY | 31.51% |
| 2015 Q4 | -3.17 Billion JPY | 11.06% |
| 2015 Q2 | -3.75 Billion JPY | 6.21% |
| 2015 FY | -3.17 Billion JPY | 23.98% |
| 2015 Q3 | -3.57 Billion JPY | 4.91% |
| 2015 Q1 | -4 Billion JPY | 4.17% |
| 2014 FY | -4.17 Billion JPY | 17.44% |
| 2014 Q2 | -4.69 Billion JPY | 3.97% |
| 2014 Q1 | -4.88 Billion JPY | 3.51% |
| 2014 Q4 | -4.17 Billion JPY | 6.87% |
| 2014 Q3 | -4.48 Billion JPY | 4.33% |
| 2013 FY | -5.06 Billion JPY | -1149.42% |
| 2013 Q4 | -5.06 Billion JPY | 0.0% |
| 2012 FY | -405.09 Million JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 230.943% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | 14.229% |
| GNI Group Ltd. | -17.93 Billion JPY | 94.577% |
| Linical Co., Ltd. | -4.46 Billion JPY | 78.209% |
| Trans Genic Inc. | -221.16 Million JPY | -339.751% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | 77.866% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 79.695% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 167.846% |
| AnGes, Inc. | -3.79 Billion JPY | 74.39% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | -131.126% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 103.905% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | -95.239% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | -108.556% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | 64.06% |
| CanBas Co., Ltd. | -1.88 Billion JPY | 48.491% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | 0.972% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | 71.369% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | 5.989% |
| Kidswell Bio Corporation | 343.58 Million JPY | 383.069% |
| PeptiDream Inc. | 3.29 Billion JPY | 129.544% |
| Ribomic Inc. | -2.09 Billion JPY | 53.68% |
| SanBio Company Limited | -3.78 Billion JPY | 74.336% |
| Healios K.K. | -2.19 Billion JPY | 55.589% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | -2.935% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | 62.937% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | 31.366% |
| StemRIM | -8.41 Billion JPY | 88.435% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 79.234% |
| FunPep Company Limited | -1.79 Billion JPY | 45.768% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | 54.477% |
| Stella Pharma Corporation | -1.11 Billion JPY | 13.115% |
| TMS Co., Ltd. | -3.44 Billion JPY | 71.781% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 82.494% |
| Cuorips Inc. | -5.56 Billion JPY | 82.51% |
| K Pharma,Inc. | -3.26 Billion JPY | 70.224% |
| Takara Bio Inc. | -32.2 Billion JPY | 96.98% |
| ReproCELL Incorporated | -2.93 Billion JPY | 66.908% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | -47.149% |
| StemCell Institute Inc. | -2.83 Billion JPY | 65.715% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | 52.932% |
| CellSeed Inc. | -2.01 Billion JPY | 51.661% |